search
Back to results

Pre-hospital Agitation and Sedation Trial: A Randomized Controlled Trial of Haloperidol Versus Midazolam for the Sedation of the Agitated Patient (PHAST)

Primary Purpose

Agitation

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Haloperidol
Midazolam
Sponsored by
Catholic Health East
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Agitation focused on measuring Time to sedation of agitated patients

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Exclusion Criteria:

  • Age <18
  • Pregnant
  • Allergic to study medication
  • Transport to hospital other than Mercy Fitzgerald Hospital
  • Unable to reach medical command prior to giving medication

Sites / Locations

  • Mercy Catholic Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Haloperidol

IM Midazolam

Arm Description

IM Haloperidol

Outcomes

Primary Outcome Measures

Time to sedation

Secondary Outcome Measures

Full Information

First Posted
December 27, 2011
Last Updated
July 22, 2019
Sponsor
Catholic Health East
search

1. Study Identification

Unique Protocol Identification Number
NCT01501123
Brief Title
Pre-hospital Agitation and Sedation Trial: A Randomized Controlled Trial of Haloperidol Versus Midazolam for the Sedation of the Agitated Patient
Acronym
PHAST
Official Title
Re-hospital Agitation and Sedation Trial: A Randomized Controlled Trial of Haloperidol Versus Midazolam for the Sedation of the Agitated Patient
Study Type
Interventional

2. Study Status

Record Verification Date
July 2019
Overall Recruitment Status
Completed
Study Start Date
November 2011 (undefined)
Primary Completion Date
October 2015 (Actual)
Study Completion Date
December 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Catholic Health East

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
PREHOSPITAL AGITATION AND SEDATION TRIAL (PHAST) The goal of the PHAST is to demine whether haloperidol is superior to midazolam for the sedation of agitated patients in the prehospital environment The primary outcome is the time to a Richmond Agitation and Sedation Scale (RASS) ≤1 o The RASS is a well validated standardized score to measure a patient's agitation The secondary outcomes are Time until RASS returns to 0 or 1 if RASS <0 Need for additional sedation Adverse effects (need for intubation, arrhythmia) Mercy EMS will be the only EMS agency in the Commonwealth of Pennsylvania carrying haloperidol Identification of potential study patients will be per state protocols Exclusion Criteria for the study Age <18 Pregnant Allergic to study medication Transport to hospital other than Mercy Fitzgerald Hospital Unable to reach medical command prior to giving medication When a paramedic identifies a possible study candidate, the paramedic will consult medical command to see if the patient is appropriate for the study If the medical command agrees the patient is appropriate for the study, patients will be randomized to Odd days: Haloperidol 5mg IM (age <65) or haloperidol 2.5 mg IM (age ≥65) Even days: Midazolam 0.05 mg IM to maximum of 5mg IM (age <65) or maximum of 2.5mg (age ≥65) The RASS will be documented by the prehospital providers every 5 minutes until arrival at the hospital Once the patient arrives at the ED, the RASS will be documented in PICIS® by the emergency department nurse at the time of triage and at a minimum of hourly until the RASS =0 or 1 for 2 consecutive hours Questions may be directed to Dr. Isenberg at disenberg@mercyhealth.org or at (267) 205-6453 Richmond Agitation Sedation Scale RASS RASS Description 4 Combative, violent, danger to staff 3 Pulls or removes tube(s) or catheters; aggressive 2 Frequent non-purposeful movement 1 Anxious, apprehensive, but not aggressive 0 Alert and calm 1 Awakens to voice (eye opening/contact) >10 sec 2 Light sedation, briefly awakens to voice (eye opening/contact) <10 sec 3 Moderate sedation, movement or eye opening. No eye contact 4 Deep sedation, no response to voice, but movement or eye opening to physical stimulation 5 Unarousable, no response to voice or physical stimulation

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Agitation
Keywords
Time to sedation of agitated patients

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Haloperidol
Arm Type
Experimental
Arm Description
IM Haloperidol
Arm Title
IM Midazolam
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Haloperidol
Intervention Description
5mg IM
Intervention Type
Drug
Intervention Name(s)
Midazolam
Intervention Description
IM midazolam
Primary Outcome Measure Information:
Title
Time to sedation
Time Frame
10 minutes

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Exclusion Criteria: Age <18 Pregnant Allergic to study medication Transport to hospital other than Mercy Fitzgerald Hospital Unable to reach medical command prior to giving medication
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Derek Isenberg, MD
Organizational Affiliation
Mercy Catholic Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mercy Catholic Medical Center
City
Darby
State/Province
Pennsylvania
ZIP/Postal Code
19023
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Pre-hospital Agitation and Sedation Trial: A Randomized Controlled Trial of Haloperidol Versus Midazolam for the Sedation of the Agitated Patient

We'll reach out to this number within 24 hrs